Thank you, Omer, and good morning, everyone. Starting with cash, we ended Q3 2024 with approximately $87.7 million in cash, cash equivalents, bank deposits, marketable securities, and short-term restricted cash on the balance sheet. Cash used in operations and capital expenditure came in at $17.7 million compared to $28.6 million in Q3 2023, and $21.6 million last quarter. We are continuing to drive sequentially decreased cash burn, resulting from our focus on Innovis 2 platform and our strong revenue performance. As Omer mentioned, we are realizing the benefits of our strategic realignment. Having reduced investments in InnovizOne development, our organization is leaner, more agile, and entirely focused on platform with InnovizTwo. I'm pleased to share that we are on track to achieve the expected saving from the realignment, reinforcing Innoviz history of financial execution. We are very proud of the trend of consistent improvement in cash burn that we have delivered over the course of the year. While there may be continued lumpiness on a sequential basis, on a fully year basis, we expect to see lower overall burn in full-year of 2024 than we saw in full-year of 2023. Looking into 2025 and beyond, we remain confident in our ability to manage our expenses effectively and keep our burn down on an annualized basis. Gross margin continue to improve quarter-over-quarter. Going forward, we expect margins will continue to be lumpy as we ramp up the InnovizTwo platform as unit volumes fluctuate and NRE revenues continue to vary from quarter-to-quarter. Now turning to the income statement, revenues for Q3 were $4.5 million compared to $3.5 million in Q3 of 2023, and in line with our guidance range of $3.5 million to $5 million. This represents another quarter in which we have delivered on the top line, extending our record of strong revenue execution. Our operating expenses for Q3 2024 were $26 million, a decrease of 6.4% from $27.8 million in Q3 2023. This quarter's operating expenses included $4.2 million of share based compensation compared to $5 million in Q3 2023. Research and development expenses for Q3 2024 were $19.7 million, a decrease from $20.7 million in Q3 2023. The quarters R&D expenses including $3 million of share based compensation compared to $3.1 million in Q3 2023. To conclude, the third quarter represents another quarter of solid performance from both revenue and cash perspective. We're encouraged by the ongoing strengths of our expense management and ability to consistently meet or exceed our revenue guidance. Looking into Q4, we expect a strong finish to the year in which we maintain lower burn while further ramping up InnovizTwo and working to secure additional design wins. With that, I'll turn the call back to Omer for a few closing remarks.